NCT02193217View on ClinicalTrials.gov

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

Not specified

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

MT-1303-Low

DRUG

MT-1303-High

DRUG

Fingolimod

DRUG

Placebo

Trial Locations (1)

Unknown

Investigational site, Leeds

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY

NCT02193217 - A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 | Biotech Hunter | Biotech Hunter